Publications of Institute of Radiopharmaceutical Cancer Research - Year 2017
12 Publications2017
An orthotopic xenograft model for high-risk non-muscle invasive bladder cancer in mice: influence of mouse strain, tumor cell count, dwell time and bladder pretreatment
Huebner, D.; Rieger, C.; Bergmann, R.; Ullrich, M.; Meister, S.; et al. (13 authors)
-
BMC Cancer 17(2017)1, 790
DOI: 10.1186/s12885-017-3778-3
Exploratory investigation of PSCA-protein expression in primary breast cancer patients reveals a link to HER2/neu overexpression.
Link, T.; Kuithan, F.; Ehninger, A.; Kuhlmann, J. D.; Kramer, M.; et al. (13 authors)
-
Oncotarget 8(2017)33, 54592-54603
DOI: 10.18632/oncotarget.17523
Mass spectrometry-based identification of a naturally presented receptor tyrosine kinase-like orphan receptor 1-derived epitope recognized by CD8+ cytotoxic T cells
Heidenreich, F.; Rücker-Braun, E.; Walz, J. S.; Eugster, A.; Kühn, D.; et al. (22 authors)
-
Haematologica -The Hematology Journal 102(2017), e460-e464
DOI: 10.3324/haematol.2017.167312
Novel Radiolabeled Bisphosphonates for PET Diagnosis and Endoradiotherapy of Bone Metastases
Pfannkuchen, N.; Meckel, M.; Bergmann, R.; Bachmann, M.; Bal, C.; et al. (9 authors)
-
Pharmaceuticals 10(2017), 45
DOI: 10.3390/ph10020045
Biological characterization of novel nitroimidazole-peptide conjugates in vitro and in vivo.
Bergmann, R.; Splith, K.; Pietzsch, J.; Bachmann, M.; Neundorf, I.
-
Journal of Peptide Science 23(2017), 597-609
DOI: 10.1002/psc.2995
Characterization of a switchable chimeric antigen receptor platform in a pre-clinical solid tumor model
Bejestani, E. P.; Cartellieri, M.; Bergmann, R.; Ehninger, A.; Loff, S.; et al. (17 authors)
-
OncoImmunology 6(2017)10, 1342909
DOI: 10.1080/2162402X.2017.1342909
Retargeting of UniCAR T cells with an in vivo synthesized target module directed against CD19 positive tumor cells
Bachmann, D.; Aliperta, R.; Bergmann, R.; Feldmann, A.; Koristka, S.; et al. (19 authors)
-
Oncotarget 9(2017), 7487-7500
DOI: 10.18632/oncotarget.23556
Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells
Mitwasi, N.; Feldmann, A.; Bergmann, R.; Berndt, N.; Arndt, C.; et al. (17 authors)
-
Oncotarget 8(2017), 108584-108603
DOI: 10.18632/oncotarget.21017
A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform
Albert, S.; Arndt, C.; Feldmann, A.; Bergmann, R.; Bachmann, D.; et al. (18 authors)
-
OncoImmunology 6(2017)4, e1287246
DOI: 10.1080/2162402X.2017.1287246
ISSN: 2162-402X
Distribution and kinetics of the Kv1.3-blocking peptide HsTX1[R14A] in experimental rats
Bergmann, R.; Kubeil, M.; Zarschler, K.; Chhabra, S.; Tajhya, R. B.; et al. (10 authors)
-
Scientific Reports 7(2017), 3756
DOI: 10.1038/s41598-017-03998-x
Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology “UniCAR”
Feldmann, A.; Arndt, C.; Bergmann, R.; Loff, S.; Cartellieri, M.; et al. (20 authors)
-
Oncotarget 8(2017)19, 31368-31385
DOI: 10.18632/oncotarget.15572
Cryogel-Supported Stem Cell Factory for Customized Sustained Release of Bispecific Antibodies for Cancer Immunotherapy
Aliperta, R.; Welzel, P. B.; Bergmann, R.; Freudenberg, R.; Berndt, N.; et al. (17 authors)
-
Scientific Reports 7(2017), 42855
DOI: 10.1038/srep42855
Years: 2021 2020 2019 2018 2017 2016 2015 2014 2013